The arrival of immunotherapies like Merck & Co.’s Keytruda and Bristol Myers’ Opdivo transformed the treatment of lung cancer. But for patients with uncommon mutations like ROS1, ALK, KRAS and EGFR, targeted drugs are a first choice for physicians.
The FDA approved Augtyro based on a trial that didn’t compare it to a placebo, and researchers knew what experimental drug they were using. Called TRIDENT-1, the trial tested Augtyro in non-small cell lung cancer patients with the ROS1 mutation whose disease had spread outside the lung.
